Phase III results: tiotropium* Respimat ® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva ® Respimat® in asthma
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Asthma: U.S. FDA approves new indication for SPIRIVA ® Respimat®
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New data show benefit of tiotropium/olodaterol Respimat ® from the start of COPD maintenance therapy
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
" European Respiratory Society International Congress 2014 TONADO ™ - further lung function and quality of life benefits with tiotropium + olodaterol Respimat® FDC* in COPD "
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Asthma: new indication for Spiriva ® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
A Case of Worsening Dyspnea and Cough
Bob is a 72-year-old male, with a 40-pack-year smoking history. He quit about 8 years ago, when severe COPD was diagnosed. Until last year, he had been stable on his regimen of Advair 250/50 and Spiriva Handihaler, other than an occasional “bronchitis,” usually treated with an antibiotic and/or steroids. Over the past year or so, however, he has noticed a marked turn for the worse. He no longer can walk up the steps in his house without stopping and gasping for breath. (Source: ConsultantLive)
Source: ConsultantLive - November 27, 2017 Category: Internal Medicine Authors: Jonathan Ilowite, MD Tags: Respiratory Diseases Source Type: news
Spiriva Respimat (Tiotropium Bromide Inhalation Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2017 Category: Drugs & Pharmacology Source Type: news
Spiriva (Tiotropium Bromide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2017 Category: Drugs & Pharmacology Source Type: news
Tiotropium for Mild to Moderate COPD Tiotropium for Mild to Moderate COPD
Is it time to consider using a daily long-acting bronchodilator like tiotropium for early-stage COPD?Medscape Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2017 Category: Consumer Health News Tags: Pulmonary Medicine Viewpoint Source Type: news
Tiotropium Effective in Mild to Moderate COPD
Daily inhaled dose tied to improvements in FEV1 compared to placebo (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 7, 2017 Category: Respiratory Medicine Tags: Internal Medicine, Pharmacy, Pulmonology, Journal, Source Type: news
Long-acting inhaler may help in early stage COPD
The inhaler medication Spiriva may help slow the progression of COPD if given in the early stages of the disease, a new study suggests. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 7, 2017 Category: Consumer Health News Source Type: news
Daily Tiotropium Confers Some Benefits in Mild-to-Moderate COPD (FREE)
By the Editors
Tiotropium is associated with benefits in stage 1 and 2 chronic obstructive pulmonary disease, according to an industry-funded study in the New England Journal of … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 7, 2017 Category: Primary Care Source Type: news
Tiotropium Boosts Lung Function in Early COPD (CME/CE)
(MedPage Today) -- Higher FEV1 at 24 months in Chinese study, but long-term impact unclear (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - September 6, 2017 Category: Respiratory Medicine Source Type: news
MassDevice.com +5 | The top 5 medtech stories for September 6, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Did Congress just kill medical device innovation?
The Medical Device User Fee Amendments bill that Congress passed this year is more than an FDA fees hike for device companies; it could inhibit innovation, says Michael Drues, a...
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news
